Drug Screening Market by Product & Services [Equipment (Immunoassay Analyzers, Chromatography Instruments, and Breath Analyzers {Semiconductor Breath Analyzers and Fuel Cell Analyzers}, Rapid Testing Devices(RTD) {Oral Fluid Testing Devices and Urine Testing Devices}), Consumables {Assay Kits, Calibrators & Controls, and Sample Collection Cups} and Laboratory Services], by Sample Type [Oral Fluid/Saliva, Breath, Hair and Other Samples {Blood & Sweat}], and by End User [Workplace & Schools, Criminal Justice Systems & Law Enforcement Agencies, Drug Testing Laboratories, Drug Treatment Centers, Hospitals, Personal Users, and Pain Management Centers] - Global Opportunity Analysis and Industry Forecast, 2017-2023 Update Available On-Demand
|
LI_171070
|
Pages: 212
|
Aug
2017 |
5838 Views
|
|
|
|
Author(s) :
Onkar Sumant and Gaurav Phalke
|
Tables: 84
|
Charts: 58
|
Formats*:
|
|
Drug Screening Market Overview:
Global Drug Screening Market is expected to reach $9,447 million in 2023 from $5,214 million in 2016 registering a CAGR of 8.7%, during the forecast period, 20172023. Drug screening test analyses biological samples, such as blood, hair, & urine; to diagnose the presence of drug abuse or its metabolites in patient’s body. Drug screening tests are used to determine if person is or was under the influences of drug at a certain point of time. Drug screening devices have improved owing to introduction of new technology; offering the users precise and accurate results. Rise in alcohol consumption among youth as well as elderly population, overuse of prescribed drugs, increase in use of narcotics and illicit drugs is a major driver for the market.
The global drug screening industry is segmented based on equipment and services, sample type, end user, and geography. Based on equipment and services, the market is divided into immunoassay analyzers, chromatography instruments, breath analyzers, breath analyzers, rapid testing devices, and urine testing devices. The breath analyzers are further classified into fuel cell breath analyzers, semiconductor breath analyzers, and other devices. The RTD (rapid testing devices) is bifurcated into urine testing devices and oral fluid/saliva testing devices. The urine testing devices are further classified into urine testing cups, dip cards and cassettes Based on consumables assay kits, sample collection cups, calibrators & controls, and other consumables. Laboratory services hold major market share in this segment. The sample type segment is divided into urine sample, breath sample, oral fluid sample, hair sample, and other sample (blood & sweat). Urines sample are widely used and draw a large amount of share in this segment. Based on end user, the industry is divided into workplace & school, drug testing laboratories, criminal justice & law enforcement agencies, hospitals, drug treatment centers, pain management centers, and personal users.
The impact of the driving factors is expected to overcome the effect of restraints. Increase in consumption of alcohol and illicit drugs, establishment of stringent laws in various countries, and increase in governmental funding to control drug trafficking provide opportunity for the drug screening devices. Immunoassay analyzers occupied the largest share in the drug screening equipment market in 2016.
Key players operating in this market include Alere, Inc., Drägerwerk AG & Co. KGAA, Abbott Laboratories, Hoffmann-La Roche AG, Biorad Laboratories, Inc., Siemens AG, Thermo Fisher Scientific, Inc., Danaher Corporation, Quest Diagnostics Incorporated and, Express Diagnostics International Inc.
Key Benefits
- The study provides an in-depth analysis of the global market with current trends and future estimations from 2016 to 2023 to elucidate the imminent investment pockets.
- Comprehensive analysis of factors that drive and restrict the market growth is provided.
- Identification of factors instrumental in changing the market scenario, rise in opportunities, and identification of key companies that can influence this market on a global & regional scale are provided.
- Key players are profiled and their strategies are analyzed thoroughly to understand the competitive outlook of the market.
Drug Screening Market Key Segments:
By Product & Service
- Equipment
- Immunoassay Analyzers
- Chromatography Instruments
- Breath Analyzers
- Fuel Cell Breathalyzers
- Semiconductor Breathalyzers
- Other Devices
- Rapid Testing Devices
- Urine Testing Devices
- Urine Testing Cups
- Dip Cards
- Cassettes
- Oral Fluid Testing Devices
- Urine Testing Devices
- Consumables
- Assay Kits
- Sample Collection Cups
- Calibrators and Controls
- Others
- Laboratory Services
By Sample Type
- Urine Sample
- Breath Sample
- Oral Fluid Sample
- Hair Sample
- Others (Blood and Sweat Samples)
By End User
- Workplace and Schools
- Drug Testing Laboratories
- Criminal Justice System & Law Enforcement Agencies
- Hospitals
- Drug Treatment Centers
- Pain Management Centers
- Personal Users
By Geography
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Taiwan
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Turkey
- Saudi Arabia
- South Africa
- Rest of LAMEA
CHAPTER 1 INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2 EXECUTIVE SUMMARY
2.1. CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. PORTER’S FIVE FORCES ANALYSIS
3.4. PATENT ANALYSIS.
3.4.1. Patent analysis, by year (2010-2016)
3.4.2. Patent analysis, by region
3.5. REGULATIONS
3.6. MARKET DYNAMICS
3.6.1. Drivers
3.6.1.1. Stringent government regulations regarding drug abuse
3.6.1.2. Rise in awareness against drug abuse
3.6.1.3. Surge in funding for drug screening
3.6.2. Restraints
3.6.2.1. Consideration of drug screening as a violation of rights
3.6.2.2. Possible manipulation of drug screening tests
3.6.3. Opportunities
3.6.3.1. Development of novel drug screening tests
3.6.3.2. Tapping the emerging markets
CHAPTER 4 DRUG SCREENING MARKET, BY PRODUCT & SERVICE
4.1. OVERVIEW
4.1.1. Market size and forecast
4.2. EQUIPMENT
4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast
4.2.4. Immunoassay analyzers
4.2.4.1. Market size & forecast
4.2.5. Chromatography instruments
4.2.5.1. Market size and forecast
4.2.6. Breath analyzers
4.2.6.1. Semiconductor breath analyzers
4.2.6.2. Fuel cell analyzers
4.2.6.3. Market size and forecast
4.3. RAPID TESTING DEVICES
4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast
4.3.3.1. Urine testing devices
4.3.3.1.1. Market size and forecast
4.3.3.1.2. Urine testing cups (value and volume estimation)
4.3.3.1.3. U.S.
4.3.3.1.3.1.1. Market size and forecast
4.3.3.1.3.1.2. Market share analysis by competitors (2012-2016)
4.3.3.1.4. Canada
4.3.3.1.4.1.1. Market size and forecast
4.3.3.1.4.1.2. Market share analysis by competitors (2012-2016)
4.3.3.1.5. UK
4.3.3.1.5.1.1. Market size and forecast
4.3.3.1.5.1.2. Market share analysis by competitors (2012-2016)
4.3.3.1.6. Taiwan
4.3.3.1.6.1.1. Market size and forecast
4.3.3.1.6.1.2. Market share analysis by competitors (2012-2016)
4.3.3.1.7. Dip cards
4.3.3.1.8. Cassettes
4.3.3.2. Oral fluid testing devices
4.3.3.2.1. Market size and forecast
4.4. CONSUMABLES
4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast
4.4.4. Assay kits
4.4.4.1. Market size and forecast
4.4.5. Sample collection cups
4.4.5.1. Market size and forecast
4.4.6. Calibrators and controls
4.4.6.1. Market size and forecast
4.4.7. Others
4.4.7.1. Market size and forecast
4.5. LABORATORY SERVICES
4.5.1. Key market trends
4.5.2. Growth factors and opportunities
4.5.3. Market size and forecast
CHAPTER 5 DRUG SCREENING MARKET, BY SAMPLE TYPE
5.1. OVERVIEW
5.1.1. Market size and forecast
5.2. URINE
5.2.1. Market size and forecast
5.3. ORAL FLUID
5.3.1. Market size and forecast
5.4. BREATH
5.4.1. Market size and forecast
5.5. HAIR
5.5.1. Market size and forecast
5.6. OTHER SAMPLES (BLOOD AND SWEAT)
5.6.1. Market size and forecast
CHAPTER 6 DRUG SCREENING MARKET, BY END USER
6.1. OVERVIEW
6.1.1. Market size and forecast
6.2. WORKPLACES AND SCHOOLS
6.2.1. Market size and forecast
6.3. CRIMINAL JUSTICE SYSTEMS AND LAW ENFORCEMENT AGENCIES
6.3.1. Market size and forecast
6.4. DRUG TESTING LABORATORIES
6.4.1. Market size and forecast
6.5. DRUG TREATMENT CENTERS
6.5.1. Market size and forecast
6.6. HOSPITALS
6.6.1. Market size and forecast
6.7. PERSONAL USERS
6.7.1. Market size and forecast
6.8. PAIN MANAGEMENT CENTERS
6.8.1. Market size and forecast
CHAPTER 7 DRUG SCREENING MARKET, BY GEOGRAPHY
7.1. OVERVIEW
7.2. NORTH AMERICA
7.2.1. Key Market Trends
7.2.2. Key growth factors and opportunities
7.2.3. Market size and forecast
7.2.3.1. U.S. market size and forecast
7.2.3.2. Canada market size and forecast
7.2.3.3. Mexico market size and forecast
7.3. EUROPE
7.3.1. Key market trends
7.3.2. Key growth factors and opportunities
7.3.3. Market size and forecast
7.3.3.1. Germany market size and forecast
7.3.3.2. UK market size and forecast
7.3.3.3. France market size and forecast
7.3.3.4. Italy market size and forecast
7.3.3.5. Rest of Europe market size and forecast
7.4. ASIA-PACIFIC
7.4.1. Key market trends
7.4.2. Key growth factors and opportunities
7.4.3. Market size and forecast
7.4.3.1. Japan market size and forecast
7.4.3.2. China market size and forecast
7.4.3.3. India market size and forecast
7.4.3.4. Australia market size and forecast
7.4.3.5. Rest of Asia-Pacific market size and forecast
7.5. LAMEA
7.5.1. Key market trends
7.5.2. Key growth factors and opportunities
7.5.3. Market size and forecast
7.5.3.1. Brazil market size and forecast
7.5.3.2. Turkey market size and forecast
7.5.3.3. South Africa market size and forecast
7.5.3.4. Rest of LAMEA market size and forecast
CHAPTER 8 COMPANY PROFILES
8.1. ALERE INC.
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.1.6. Key strategic moves and developments
8.2. DRAGERWERK AG & CO. KGAA
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.3. ABBOTT LABORATORIES
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance
8.3.6. Key strategic moves and developments
8.4. BIO-RAD LABORATORIES, INC.
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.4.5. Business performance
8.5. DANAHER CORPORATION
8.5.1. Company overview
8.5.2. Company Snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Business performance
8.5.6. Key strategic moves and developments
8.6. EXPRESS DIAGNOSTICS INTERNATIONAL INC.
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Key strategic moves and developments
8.7. F. HOFFMANN-LA ROCHE AG (ROCHE DIAGNOSTICS)
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.7.6. Key strategic moves and developments
8.8. QUEST DIAGNOSTICS INCORPORATED
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance
8.9. SIEMENS AKTIENGESELLSCHAFT
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating segments
8.9.4. Product portfolio
8.9.5. Business performance
8.9.6. Key strategic moves and developments
8.10. THERMO FISHER SCIENTIFIC INC.
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.5. Business performance
8.10.6. Key strategic moves and developments
LIST OF TABLES
TABLE 1. GLOBAL DRUG SCREENING MARKET, BY PRODUCT & SERVICE, 2016-2023 ($MILLION)
TABLE 2. DRUG SCREENING MARKET FOR EQUIPMENT, BY TYPE, 2016-2023 ($MILLION)
TABLE 3. DRUG SCREENING MARKET FOR EQUIPMENT, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 4. DRUG SCREENING MARKET FOR IMMUNOASSAY ANALYZERS, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 5. DRUG SCREENING MARKET FOR CHROMATOGRAPHY INSTRUMENTS, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 6. DRUG SCREENING MARKET FOR BREATH ANALYZERS, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 7. DRUG SCREENING RAPID TESTING DEVICES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 8. DRUG SCREENING MARKET FOR RAPID TESTING DEVICES, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 9. DRUG SCREENING MARKET FOR URINE TESTING DEVICES, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 10. U.S. DRUG SCREENING MARKET FOR URINE TESTING CUPS, BY VALUE AND VOLUME, 2016-2023 ($THOUSAND AND THOUSAND UNITS)
TABLE 11. U.S.MARKET SHARE ANALYSIS IN PERCENTAGE FOR URINE TESTING CUPS (2012-2016)
TABLE 12. CANADA DRUG SCREENING MARKET FOR URINE TESTING CUPS, BY VALUE AND VOLUME, 2016-2023 ($THOUSAND AND THOUSAND UNITS)
TABLE 13. CANADA MARKET SHARE ANALYSIS IN PERCENTAGE FOR URINE TESTING CUPS (2012-2016)
TABLE 14. UK DRUG SCREENING MARKET FOR URINE TESTING CUPS, BY VALUE AND VOLUME, 2016-2023 ($THOUSAND AND THOUSAND UNITS)
TABLE 15. UK MARKET SHARE ANALYSIS IN PERCENTAGE FOR URINE TESTING CUPS (2012-2016)
TABLE 16. TAIWAN DRUG SCREENING MARKET FOR URINE TESTING CUPS, BY VALUE AND VOLUME, 2016-2023 ($THOUSAND AND THOUSAND UNITS)
TABLE 17. TAIWAN MARKET SHARE ANALYSIS IN PERCENTAGE FOR URINE TESTING CUPS (2012-2016)
TABLE 18. DRUG SCREENING MARKET FOR ORAL FLUID TESTING DEVICES, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 19. GLOBAL DRUG SCREENING MARKET FOR CONSUMABLES, BY TYPE, 2016-2023 ($MILLION)
TABLE 20. DRUG SCREENING MARKET FOR CONSUMABLES, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 21. DRUG SCREENING MARKET FOR ASSAY KITS, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 22. DRUG SCREENING MARKET FOR SAMPLE COLLECTION CUPS, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 23. DRUG SCREENING MARKET FOR CALIBRATORS AND CONTROLS, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 24. DRUG SCREENING MARKET FOR OTHERS CONSUMABLES, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 25. DRUG SCREENING MARKET FOR LABORATORY SERVICES, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 26. GLOBAL DRUG SCREENING MARKET, BY SAMPLE TYPE, 2016-2023 ($MILLION)
TABLE 27. DRUG SCREENING MARKET FOR URINE SAMPLE, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 28. DRUG SCREENING MARKET FOR ORAL FLUID SAMPLE, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 29. DRUG SCREENING MARKET FOR BREATH SAMPLE, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 30. DRUG SCREENING MARKET FOR HAIR SAMPLE, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 31. DRUG SCREENING MARKET FOR OTHER SAMPLES, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 32. GLOBAL DRUG SCREENING MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 33. DRUG SCREENING MARKET FOR WORKPLACE AND SCHOOLS, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 34. DRUG SCREENING MARKET FOR CRIMINAL INVESTIGATION SERVICES & LAW ENFORCEMENT AGENCIES, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 35. DRUG SCREENING MARKET FOR DRUG TESTING LABORATORIES, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 36. DRUG SCREENING MARKET FOR DRUG TREATMENT CENTERS, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 37. DRUG SCREENING MARKET FOR HOSPITALS, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 38. DRUG SCREENING MARKET FOR PERSONAL USERS, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 39. DRUG SCREENING MARKET FOR PAIN MANAGEMENT CENTERS, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 40. NORTH AMERICA DRUG SCREENING MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 41. NORTH AMERICA DRUG SCREENING MARKET, BY PRODUCT AND SERVICE, 2016-2023, ($MILLION)
TABLE 42. NORTH AMERICA DRUG SCREENING MARKET, BY SAMPLE TYPE, 2016-2023, ($MILLION)
TABLE 43. NORTH AMERICA DRUG SCREENING MARKET, BY END USER, 2016-2023, ($MILLION)
TABLE 44. EUROPE DRUG SCREENING MARKET, BY COUNTRY, 2016-2023, ($MILLION)
TABLE 45. EUROPE DRUG SCREENING MARKET, BY PRODUCT AND SERVICE, 2016-2023 ($MILLION)
TABLE 46. EUROPE DRUG SCREENING MARKET, BY SAMPLE TYPE, 2016-2023 ($MILLION)
TABLE 47. EUROPE DRUG SCREENING MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 48. ASIA-PACIFIC DRUG SCREENING MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 49. ASIA-PACIFIC DRUG SCREENING MARKET, BY PRODUCT AND SERVICE, 2016-2023 ($MILLION)
TABLE 50. ASIA-PACIFIC DRUG SCREENING MARKET, BY SAMPLE TYPE, 2016-2023 ($MILLION)
TABLE 51. ASIA-PACIFIC DRUG SCREENING MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 52. LAMEA DRUG SCREENING MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 53. LAMEA DRUG SCREENING MARKET, BY PRODUCT AND SERVICE, 2016-2023 ($MILLION)
TABLE 54. LAMEA DRUG SCREENING MARKET, BY SAMPLE TYPE, 2016-2023 ($MILLION)
TABLE 55. LAMEA DRUG SCREENING MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 56. ALERE: COMPANY SNAPSHOT
TABLE 57. ALERE: OPERATING SEGMENTS
TABLE 58. ALERE: PRODUCT PORTFOLIO
TABLE 59. DRAGER: COMPANY SNAPSHOT
TABLE 60. DRAGER: PRODUCT CATEGORIES
TABLE 61. DRAGER: PRODUCT PORTFOLIO
TABLE 62. ABBOTT: COMPANY SNAPSHOT
TABLE 63. ABBOTT: OPERATING SEGMENTS
TABLE 64. ABBOTT: PRODUCT PORTFOLIO
TABLE 65. BIO-RAD: COMPANY SNAPSHOT
TABLE 66. BIO-RAD: OPERATING SEGMENTS
TABLE 67. BIO-RAD: PRODUCT PORTFOLIO
TABLE 68. DANAHER: COMPANY SNAPSHOT
TABLE 69. DANAHER: OPERATING SEGMENTS
TABLE 70. DANAHER: PRODUCT PORTFOLIO
TABLE 71. EXPRESS DIAGNOSTICS: COMPANY SNAPSHOT
TABLE 72. EXPRESS DIAGNOSTICS: OPERATING SEGMENTS
TABLE 73. ROCHE: COMPANY SNAPSHOT
TABLE 74. ROCHE: OPERATING SEGMENT
TABLE 75. ROCHE: PRODUCT PORTFOLIO
TABLE 76. QUEST DIAGNOSTICS: COMPANY SNAPSHOT
TABLE 77. QUEST DIAGNOSTICS: OPERATING SEGMENTS
TABLE 78. QUEST DIAGNOSTICS: PRODUCT PORTFOLIO
TABLE 79. SIEMENS: COMPANY SNAPSHOT
TABLE 80. SEIMENS: OPERATING SEGMENTS
TABLE 81. SIEMENS: PRODUCT PORTFOLIO
TABLE 82. THERMO FISHER: COMPANY SNAPSHOT
TABLE 83. THERMO FISHER: OPERATING SEGMENTS
TABLE 84. THERMO FISHER: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 1. GLOBAL DRUG SCREENING MARKET SEGMENTATION
FIGURE 2. TOP INVESTMENT POCKETS IN GLOBAL DRUG SCREENING MARKET
FIGURE 3. TOP WINNING STRATEGIES: PERCENTAGE AND DISTRIBUTION
FIGURE 4. TOP WINNING STRATEGIES: TYPE AND COMPANY
FIGURE 5. TOP WINNING STRATEGIES: TYPE AND NATURE
FIGURE 6. BARGAINING POWER OF BUYERS
FIGURE 7. BARGAINING POWER OF SUPPLIERS
FIGURE 8. THREAT OF NEW ENTRANTS
FIGURE 9. THREAT OF SUBSTITUTION
FIGURE 10. COMPETITIVE RIVALRY
FIGURE 11. PATENT REGISTERED/APPROVED, BY YEAR (2010-2016)
FIGURE 12. PATENT REGISTERED/APPROVED, BY REGION (2010-2016)
FIGURE 13. GLOBAL DRUG SCREENING MARKET: DRIVERS & RESTRAINTS
FIGURE 14. DRUG SCREENING PRODUCT AND SERVICE SEGMENTATION
FIGURE 15. DRUG SCREENING SAMPLE TYPE SEGMENTATION
FIGURE 16. DRUG SCREENING MARKET END USER SEGMENTATION
FIGURE 17. U.S. DRUG SCREENING MARKET, 2016-2023 ($MILLION)
FIGURE 18. CANADA DRUG SCREENING MARKET, 2016-2023 ($MILLION)
FIGURE 19. MEXICO DRUG SCREENING MARKET, 2016-2023 ($MILLION)
FIGURE 20. GERMANY DRUG SCREENING MARKET, 2016-2023 ($MILLION)
FIGURE 21. UK DRUG SCREENING MARKET, 2016-2023 ($MILLION)
FIGURE 22. FRANCE DRUG SCREENING MARKET, 2016-2023 ($MILLION)
FIGURE 23. ITALY DRUG SCREENING MARKET, 2016-2023 ($MILLION)
FIGURE 24. REST OF EUROPE DRUG SCREENING MARKET, 2016-2023 ($MILLION)
FIGURE 25. JAPAN DRUG SCREENING MARKET, 2016-2023 ($MILLION)
FIGURE 26. CHINA DRUG SCREENING MARKET, 2016-2023 ($MILLION)
FIGURE 27. INDIA DRUG SCREENING MARKET, 2016-2023 ($MILLION)
FIGURE 28. AUSTRALIA DRUG SCREENING MARKET, 2016-2023 ($MILLION)
FIGURE 29. REST OF ASIA-PACIFIC DRUG SCREENING MARKET, 2016-2023 ($MILLION)
FIGURE 30. BRAZIL DRUG SCREENING MARKET, 2016-2023 ($MILLION)
FIGURE 31. TURKEY DRUG SCREENING MARKET, 2016-2023 ($MILLION)
FIGURE 32. SOUTH AFRICA DRUG SCREENING MARKET, 2016-2023 ($MILLION)
FIGURE 33. REST OF LAMEA DRUG SCREENING MARKET, 2016-2023 ($MILLION)
FIGURE 34. ALERE: NET SALES, 2014-2016 ($MILLION)
FIGURE 35. ALERE: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 36. ALERE: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 37. DRAGER: NET SALES, 2014-2016 ($MILLION)
FIGURE 38. DRAGER: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 39. ABBOTT: NET SALES, 2014-2016 ($MILLION)
FIGURE 40. ABBOTT: REVENUE BY SEGMENT, 2016 (%)
FIGURE 41. ABBOTT: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 42. BIO-RAD: NET SALES, 2014-2016 ($MILLION)
FIGURE 43. BIO-RAD: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 44. BIO-RAD: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 45. DANAHER: NET SALES, 2014-2016 ($MILLION)
FIGURE 46. DANAHER: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 47. DANAHER: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 48. ROCHE: NET SALES, 2014-2016 ($MILLION)
FIGURE 49. ROCHE: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 50. ROCHE: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 51. QUEST DIAGNOSTICS: NET SALES, 2014-2016 ($MILLION)
FIGURE 52. QUEST DIAGNOSTICS: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 53. SIEMENS: NET SALES, 2014-2016 ($MILLION)
FIGURE 54. SIEMENS: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 55. SIEMENS: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 56. THERMO FISHER: NET SALES, 2014-2016 ($MILLION)
FIGURE 57. THERMO FISHER: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 58. THERMO FISHER: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
Drug abuse in work force can result in reduced productivity, absenteeism, injuries and accidents, poor decision making. In schools and colleges drug abuse can alter brain function and affect development of brain in students. Due to this reason, many employers and educational institutes have mandated the drug screening tests to be conducted before the admission of the candidates. More and more employers are turning towards a drug free workplace and thus boosting the growth of drug screening market. Many employers have initiated programs to help the workforce with the drug abuse problems, such as employee assistance program (EAP). These kind of programs provide complete employee assistance such as long term and short term counselling, marital and family problems, financial distress and any other personal problem that can affect employee’s work.
Drug screening has positively rewarded individuals and societies with the power of regulation and a drug free healthy environment. Schools and workplaces have made drugs tests mandatory due to familiarity of adverse effects of drugs and alcohol consumption. The government initiatives for research and development of drugs screening devices and to tackle the illegal drug trafficking are major drivers of the drug screening market.
Developed countries such as U.S. have established stringent laws to control the drug abuse problem, moreover increasing disposable income in developing countries have raised market potential for drug screening devices as untapped markets. However, countries with supplementary laws to protect privacy on an individual can hinder the growth of this market. Drug testing in such countries can be considered as invasion of individual’s privacy. Moreover, drugs test such as urine test which is widely used is not always accurate and can be manipulated. In order to overcome these limitations companies are coming up with new technologies such as (RTD) rapid testing devices and exploring other sample types such as hair sample, saliva sample to achieve precise results and results over long term drug abuse.
Currently hair sample is a fastest growing segment due to its prolonged detection period of drug abuse and precision level of result, hair sample segment is anticipated to grow at a significant rate during the forecast period. Workplace and schools at present are the largest end users of the drug screening devices. Increase in awareness regarding drug abuse has led to increase in personal users and this segment is expected to grow at fastest rate during the forecast period. Followed by law enforcement agencies because of firm government policies regarding drug abuse. Drug screening market is well established in North America owing to its application and awareness in the region. Developing countries are also working towards establishing strict laws and regulations regarding drug abuse due to its harmful effects on the individuals and society.
Download Sample
Purchase Full Report of
Drug Screening Market- Global Opportunity Analysis and Industry Forecast, 2017-2023
- Online Only
- $4,769
- Online cloud access only
- Restricted print, copy, paste & download
- Read only
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
- Data Pack
- $5,299
- Restricted to one authorized user
- One print only
- Available in Excel
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
- Single User
- $7,411
- Restricted to one authorized user
- One print only
- Available in Excel & PDF
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
- Five Users
- $8,901
- Limited to five authorized users
- Print upto five copies
- Available in Excel & PDF
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
-
Enterprise
License/PDF - $12,413
- Unlimited within company/enterprise
- Available in Excel & PDF
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
Why Allied Market Research?
Infallible Methodology
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
Analyst Support
For complete satisfaction
Customization
On-demand customization of scope of the report to exactly meet your needs
TARGETED MARKET VIEW
Targeted market view to provide pertinent information and save time of readers
Get fresh content delivered
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Buy Full Version
"Drug Screening Market"
Purchase Enquiry